Review
Published on 25 Jul 2024
Ligand-conjugated multiwalled carbon nanotubes for cancer targeted drug delivery
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1417399
- 1,538 views
- 1 citation
Type at least 3 characters
932 articles
Articles
Review
Published on 25 Jul 2024
Bibliometric and visualized analysis of ultrasound combined with microbubble therapy technology from 2009 to 2023
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1418142
- 1,168 views
Original Research
Published on 22 Jul 2024
Pan-cancer analyses reveal the molecular and clinical characteristics of TET family members and suggests that TET3 maybe a potential therapeutic target
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1418456
- 1,226 views
Review
Published on 18 Jul 2024
Bibliometric analysis of vitamin D and obesity research over the period 2000 to 2023
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1445061
- 1,708 views
Original Research
Published on 18 Jul 2024
Identifying potential therapeutic targets in lung adenocarcinoma: a multi-omics approach integrating bulk and single-cell RNA sequencing with Mendelian randomization
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1433147
- 2,503 views
Editorial
Published on 16 Jul 2024
Editorial: Incorporating Phase 0 microdosing as a powerful tool into a new vision of drug development
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1455643
- 596 views
Clinical Trial
Published on 15 Jul 2024
A phase 1, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-1905, a long-acting anti-thymic stromal lymphopoietin antibody, in healthy subjects
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1400696
- 2,788 views
- 1 citation
Original Research
Published on 10 Jul 2024
Repurposing the Open Global Health Library for the discovery of novel Mpro destabilizers with scope as broad-spectrum antivirals
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1390705
- 810 views
Original Research
Published on 03 Jul 2024
Individualized, dynamic, and full-course vancomycin dosing prediction: a study on the customized dose model
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1414347
- 822 views
Opinion
Published on 02 Jul 2024
Life scientists improve QSP model quality and impact
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1392747
- 771 views
Case Report
Published on 27 Jun 2024
Case report: dose-dependent interaction between dexamethasone and voriconazole in severely ill patients with non-Hodgkin’s lymphoma being treated for invasive pulmonary aspergillosis
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1403966
- 957 views
- 1 citation
Case Report
Published on 19 Jun 2024
Case report and literature review: management of Paxlovid (nirmatrelvir/ritonavir)-induced acute tacrolimus toxicity in a patient with systemic lupus erythematosus
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1364121
- 1,432 views
Clinical Trial
Published on 12 Jun 2024
Safety, tolerability, pharmacokinetics, and pharmacodynamics of a soluble guanylate cyclase stimulator, HEC95468, in healthy volunteers: a randomized, double-blinded, placebo-controlled phase 1 trial
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1359939
- 1,274 views
Opinion
Published on 10 Jun 2024
Translational pathology in drug discovery
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1409092
- 828 views
Original Research
Published on 03 Jun 2024
Translational PK/PD and the first-in-human dose selection of a PD1/IL15: an engineered recombinant targeted cytokine for cancer immunotherapy
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1380000
- 1,934 views
Original Research
Published on 30 May 2024
Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1402138
- 3,368 views